Laurie Fenton Ambrose explains breakthrough advance in extensive-stage small cell lung cancer – Amgen Oncology

Amgen Oncology shared on LinkedIn:

“A breakthrough advance in extensive-stage small cell lung cancer (ES-SCLC) care is here.

Amgen’s immunotherapy is uniquely tailored to people with ES-SCLC, explains Laurie Fenton Ambrose of GO2 for Lung Cancer.

This innovative treatment works by empowering a patient’s own immune system to seek out and help destroy SCLC cells.”

Additional information.
Link to video attached to the post.
Source: Amgen Oncology/LinkedIn